BindingDB logo
myBDB logout

100 articles for thisTarget


The following articles (labelled with PubMed ID or TBD) are for your review
PMIDDataArticle TitleOrganization
27914947 11 Synthesis and binding monitoring of a new nanomolar PAMAM-based matrix metalloproteinases inhibitor (MMPIs).EBI University of Florence
27825552 152 Design, synthesis, and biological activity of novel, potent, and highly selective fused pyrimidine-2-carboxamide-4-one-based matrix metalloproteinase (MMP)-13 zinc-binding inhibitors.EBI Takeda Pharmaceutical Company Limited
26653735 81 Discovery of N-(4-Fluoro-3-methoxybenzyl)-6-(2-(((2S,5R)-5-(hydroxymethyl)-1,4-dioxan-2-yl)methyl)-2H-tetrazol-5-yl)-2-methylpyrimidine-4-carboxamide. A Highly Selective and Orally Bioavailable Matrix Metalloproteinase-13 Inhibitor for the Potential Treatment of Osteoarthritis.EBI Pfizer Inc.
26753813 22 Design and synthesis of an activity-based protein profiling probe derived from cinnamic hydroxamic acid.EBI University of Minnesota
25264600 64 Discovery of novel, highly potent, and selective quinazoline-2-carboxamide-based matrix metalloproteinase (MMP)-13 inhibitors without a zinc binding group using a structure-based design approach.EBI Takeda Pharmaceutical Company Limited
25265401 38 Targeting matrix metalloproteinases: exploring the dynamics of the s1' pocket in the design of selective, small molecule inhibitors.EBI Universidad CEU San Pablo
25192810 66 Thieno[2,3-d]pyrimidine-2-carboxamides bearing a carboxybenzene group at 5-position: highly potent, selective, and orally available MMP-13 inhibitors interacting with the S1 binding site.EBI Takeda Pharmaceutical Company Ltd
24044937 59 Aggrecanase-2 inhibitors based on the acylthiosemicarbazide zinc-binding group.EBI INSERM
23631440 44 Matrix metalloproteinase inhibitors based on the 3-mercaptopyrrolidine core.EBI Florida State University
23437776 37 Optimization of peptide hydroxamate inhibitors of insulin-degrading enzyme reveals marked substrate-selectivity.EBI Mayo Clinic
17275314 701 Matrix metalloproteinases (MMPs): chemical-biological functions and (Q)SARs.EBI Pomona College
21780776 40 Remarkable potential of thea-aminophosphonate/phosphinate structural motif in medicinal chemistry.EBI Wroclaw University of Technology
22175799 22 Discovery and evaluation of a non-Zn chelating, selective matrix metalloproteinase 13 (MMP-13) inhibitor for potential intra-articular treatment of osteoarthritis.EBI Alantos Pharmaceuticals AG
19715320 87 Grassystatins A-C from marine cyanobacteria, potent cathepsin E inhibitors that reduce antigen presentation.EBI University of Florida
18053726 364 Inhibitors of proteases and amide hydrolases that employ an alpha-ketoheterocycle as a key enabling functionality.EBI Johnson& Johnson Pharmaceutical Research& Development
18251495 69 Quinazolinones and pyrido[3,4-d]pyrimidin-4-ones as orally active and specific matrix metalloproteinase-13 inhibitors for the treatment of osteoarthritis.EBI Pfizer Inc.
18061445 103 Alpha,beta-cyclic-beta-benzamido hydroxamic acids: novel templates for the design, synthesis, and evaluation of selective inhibitors of TNF-alpha converting enzyme (TACE).EBI Bristol-Myers Squibb Research and Development
17127067 21 Methotrexate gamma-hydroxamate derivatives as potential dual target antitumor drugs.EBI Instituto Superior T£cnico
15713379 40 N-i-Propoxy-N-biphenylsulfonylaminobutylhydroxamic acids as potent and selective inhibitors of MMP-2 and MT1-MMP.EBI Universit£ degli Studi di Pisa
12773042 195 Synthesis and structure-activity relationship of N-substituted 4-arylsulfonylpiperidine-4-hydroxamic acids as novel, orally active matrix metalloproteinase inhibitors for the treatment of osteoarthritis.EBI Wyeth Research
11472217 157 Design, synthesis, and structure-activity relationships of macrocyclic hydroxamic acids that inhibit tumor necrosis factor alpha release in vitro and in vivo.EBI DuPont Pharmaceuticals Company
11472202 143 Potent and selective carboxylic acid-based inhibitors of matrix metalloproteinases.EBI TBA
10669559 180 Protease inhibitors: current status and future prospects.EBI University of Queensland
10649971 180 Structure-activity relationships and pharmacokinetic analysis for a series of potent, systemically available biphenylsulfonamide matrix metalloproteinase inhibitors.EBI Parke-Davis Pharmaceutical Research
10882358 62 Hydroxamic acid derivatives as potent peptide deformylase inhibitors and antibacterial agents.EBI F. Hoffmann-La Roche Ltd.
10579818 162 Design, synthesis, and biological evaluation of potent thiazine- and thiazepine-based matrix metalloproteinase inhibitors.EBI Procter and Gamble Pharmaceuticals
9888835 42 Design and synthesis of phosphinamide-based hydroxamic acids as inhibitors of matrix metalloproteinases.EBI Procter and Gamble Pharmaceuticals
9733482 31 Discovery of potent, achiral matrix metalloproteinase inhibitors.EBI Procter and Gamble Pharmaceuticals
11327577 86 Heterocycle-based MMP inhibitors with P2' substituents.EBI Procter and Gamble Pharmaceuticals
22175825 19 Potent inhibitors of LpxC for the treatment of Gram-negative infections.EBI Pfizer Inc.
22017539 75 Fragment-based discovery of indole inhibitors of matrix metalloproteinase-13.EBI Boehringer Ingelheim Pharmaceuticals Inc
22017477 35 Novel 1-hydroxypiperazine-2,6-diones as new leads in the inhibition of metalloproteinases.EBI Instituto Superior T£cnico
22153340 37 Discovery of potent and selective matrix metalloprotease 12 inhibitors for the potential treatment of chronic obstructive pulmonary disease (COPD).EBI Pfizer Inc.
21866961 28 Selective water-soluble gelatinase inhibitor prodrugs.EBI University of Notre Dame
20726512 282 Orally active MMP-1 sparinga-tetrahydropyranyl anda-piperidinyl sulfone matrix metalloproteinase (MMP) inhibitors with efficacy in cancer, arthritis, and cardiovascular disease.EBI Pfizer Inc.
20638281 56 Structure and activity relationships of tartrate-based TACE inhibitors.EBI Merck Research Laboratories
21507637 102 MMP-13 selectivea-sulfone hydroxamates: a survey of P1' heterocyclic amide isosteres.EBI Pfizer Inc.
21458257 87 2-(2-Aminothiazol-4-yl)pyrrolidine-based tartrate diamides as potent, selective and orally bioavailable TACE inhibitors.EBI Merck Research Laboratories
20965620 50 Structure-based approach to nanomolar, water soluble matrix metalloproteinases inhibitors (MMPIs).EBI ProtEra s.r.l.
21106451 39 Novel TNF-a converting enzyme (TACE) inhibitors as potential treatment for inflammatory diseases.EBI Merck Research Laboratories
20529684 112 Orally bioavailable dual MMP-1/MMP-14 sparing, MMP-13 selective alpha-sulfone hydroxamates.EBI Pfizer Research& Development
20172725 49 Discovery and SAR of hydantoin TACE inhibitors.EBI Merck Research Laboratories
20022498 71 The discovery of novel tartrate-based TNF-alpha converting enzyme (TACE) inhibitors.EBI Schering-Plough Research Institute Cambridge
20005097 58 Discovery of (pyridin-4-yl)-2H-tetrazole as a novel scaffold to identify highly selective matrix metalloproteinase-13 inhibitors for the treatment of osteoarthritis.EBI Pfizer Inc.
19703773 63 The identification of beta-hydroxy carboxylic acids as selective MMP-12 inhibitors.EBI GSK Medicines Research Centre
19524436 27 Regioselective synthesis of methylated epigallocatechin gallate via nitrobenzenesulfonyl (Ns) protecting group.EBI University of Shizuoka and Global COE Program
19725580 93 Identification of an orally efficacious matrix metalloprotease 12 inhibitor for potential treatment of asthma.EBI Wyeth Research
18835710 69 Discovery of novel hydroxamates as highly potent tumor necrosis factor-alpha converting enzyme inhibitors. Part II: optimization of the S3' pocket.EBI Schering Plough Research Institute
 96 Inhibition of Matrix Metalloproteinases: An examination of the S1′ pocketEBI TBA
 36 Design, synthesis, activity, and structure of a novel class of matrix metalloproteinase inhibitors containing a heterocyclic P2′-P3′ amide bond isostereEBI TBA
 40 Novel indolactam-based inhibitors of matrix metalloproteinasesEBI TBA
18790648 317 Specific targeting of metzincin family members with small-molecule inhibitors: progress toward a multifarious challenge.EBI University of Athens
18782669 90 Introduction of the 4-(4-bromophenyl)benzenesulfonyl group to hydrazide analogs of Ilomastat leads to potent gelatinase B (MMP-9) inhibitors with improved selectivity.EBI Université de Reims-Champagne-Ardenne
18442906 40 Novel bis-(arylsulfonamide) hydroxamate-based selective MMP inhibitors.EBI North Dakota State University
17719700 39 Peptidyl 3-substituted 1-hydroxyureas as isosteric analogues of succinylhydroxamate MMP inhibitors.EBI Università G. d'Annunzio
17623656 34 Discovery and characterization of a novel inhibitor of matrix metalloprotease-13 that reduces cartilage damage in vivo without joint fibroplasia side effects.EBI Pfizer Global Research and Development
17576061 132 Synthesis and structure-activity relationship of a novel, non-hydroxamate series of TNF-alpha converting enzyme inhibitors.EBI Bristol-Myers Squibb Pharmaceutical Research Institute
17368021 55 Hydantoins, triazolones, and imidazolones as selective non-hydroxamate inhibitors of tumor necrosis factor-alpha converting enzyme (TACE).EBI Bristol-Myers Squibb Pharmaceutical Research Institute
17276676 112 A new 4-(2-methylquinolin-4-ylmethyl)phenyl P1' group for the beta-amino hydroxamic acid derived TACE inhibitors.EBI Bristol-Myers Squibb Pharmaceutical Research Institute
17088065 106 alpha-Biphenylsulfonylamino 2-methylpropyl phosphonates: enantioselective synthesis and selective inhibition of MMPs.EBI Università "G. d'Annunzio"
17027261 153 Discovery of low nanomolar non-hydroxamate inhibitors of tumor necrosis factor-alpha converting enzyme (TACE).EBI Bristol-Myers Squibb Pharmaceutical Research Institute
16516466 175 Synthesis and structure-activity relationship of a novel, achiral series of TNF-alpha converting enzyme inhibitors.EBI Bristol-Myers Squibb Pharmaceutical Research Institute
16473009 23 Synthesis and evaluation of succinoyl-caprolactam gamma-secretase inhibitors.EBI Bristol-Myers Squibb Pharmaceutical Research Institute
16392792 29 Matrix metalloproteinase target family landscape: a chemometrical approach to ligand selectivity based on protein binding site analysis.EBI Aventis Pharma Deutschland GmbH
16153831 87 Synthesis and SAR of highly selective MMP-13 inhibitors.EBI Wyeth Research
16005220 52 Identification of potent and selective MMP-13 inhibitors.EBI Wyeth Research
14711305 26 Evaluation of P1'-diversified phosphinic peptides leads to the development of highly selective inhibitors of MMP-11.EBI University of Athens
14684295 109 Tetrahydroisoquinoline based sulfonamide hydroxamates as potent matrix metalloproteinase inhibitors.EBI Chinese Academy of Sciences
12877590 28 A potent, selective inhibitor of matrix metalloproteinase-3 for the topical treatment of chronic dermal ulcers.EBI Pfizer Global Research and Development
12798337 6 Synthesis of radiolabeled biphenylsulfonamide matrix metalloproteinase inhibitors as new potential PET cancer imaging agents.EBI Indiana University School of Medicine
12408705 73 Discovery of gamma-lactam hydroxamic acids as selective inhibitors of tumor necrosis factor alpha converting enzyme: design, synthesis, and structure-activity relationships.EBI Bristol-Myers Squibb Company
11754593 148 Phenoxyphenyl sulfone N-formylhydroxylamines (retrohydroxamates) as potent, selective, orally bioavailable matrix metalloproteinase inhibitors.EBI Abbott Laboratories
11585440 76 Discovery of macrocyclic hydroxamic acids containing biphenylmethyl derivatives at P1', a series of selective TNF-alpha converting enzyme inhibitors with potent cellular activity in the inhibition of TNF-alpha release.EBI DuPont Pharmaceuticals Company
11551755 18 Asymmetric synthesis of BB-3497--a potent peptide deformylase inhibitor.EBI British Biotech Pharmaceuticals Limited
11454461 111 The development of new carboxylic acid-based MMP inhibitors derived from a cyclohexylglycine scaffold.EBI Procter and Gamble Pharmaceuticals
11412980 48 Discovery and characterization of the potent, selective and orally bioavailable MMP inhibitor ABT-770.EBI Abbott Laboratories
11327602 58 Novel 5,5-disubstitutedpyrimidine-2,4,6-triones as selective MMP inhibitors.EBI Roche Research Center
11150165 228 Development of new hydroxamate matrix metalloproteinase inhibitors derived from functionalized 4-aminoprolines.EBI Procter and Gamble Pharmaceuticals
10669564 189 Design and synthesis of piperazine-based matrix metalloproteinase inhibitors.EBI Procter and Gamble Pharmaceuticals
10639284 119 Design, synthesis, and biological evaluation of matrix metalloproteinase inhibitors derived from a modified proline scaffold.EBI University of Florida
10411481 144 Phosphinic pseudo-tripeptides as potent inhibitors of matrix metalloproteinases: a structure-activity study.EBI CEA
9873712 109 Aryl ketones as novel replacements for the C-terminal amide bond of succinyl hydroxamate MMP inhibitors.EBI Abbott Laboratory
9873491 56 The design, synthesis, and structure-activity relationships of a series of macrocyclic MMP inhibitors.EBI Abbott Laboratories
9632351 36 Rational design and combinatorial evaluation of enzyme inhibitor scaffolds: identification of novel inhibitors of matrix metalloproteinases.EBI Affymax Research Institute
9484512 130 Highly selective and orally active inhibitors of type IV collagenase (MMP-9 and MMP-2): N-sulfonylamino acid derivatives.EBI Shionogi & Co., Ltd.
21524149 13 Design, synthesis and pharmacological evaluation of conformationally restricted N-arylsulfonyl-3-aminoalkoxy indoles as a potential 5-HT6 receptor ligands.BDB Suven Life Sciences Ltd
8632342 110 Pharmacologic characterization of the human 5-hydroxytryptamine2B receptor: evidence for species differences.BDB Eli Lilly and Company
7651361 32 Characterization of (+/-)(-)[3H]epibatidine binding to nicotinic cholinergic receptors in rat and human brain.BDB Georgetown University
7518496 9 Cloning and expression of a 5-hydroxytryptamine7 receptor positively coupled to adenylyl cyclase.BDB Syntex Discovery Research
7515823 54 Actions of phenylglycine analogs at subtypes of the metabotropic glutamate receptor family.BDB Novo Nordisk A/S
7509389 8 Pharmacological profile of FK480, a novel cholecystokinin type-A receptor antagonist: comparison to loxiglumide.BDB Fujisawa Pharmaceutical Co. Ltd.